StemCell Therapy

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patients cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interest in the sector appears to have died down considerably, on account of high R&D spending and delays companies have seen in launching revenue-generating products. Our indicative theme of Gene-Based Therapy Stocks is down by about -23% year-to-date, underperforming the S&P 500 which is up by about 2%. However, with valuations declining, these companies could be attractive bets for investors as years of investments potentially start to pay off. These companies could also be acquisition candidates for big pharma. Below is a bit more about these companies and how they have fared this year.

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that develops RNA-targeted therapeutics and gene therapy products. The company recently provided some positive data on its investigational gene therapy for Duchenne muscular dystrophy. The stock is up 11% year-to-date.

SRPT

Voyager Therapeutics is a clinical-stage biotech company that is developing gene therapies for Parkinsons disease, Huntingtons disease, and other conditions. The stock is down by about -20% year-to-date.

REGENXBIO Inc.: is a clinical-stage biotechnology company working on gene-based therapies for Retinal diseases, Hunter and Hurler syndromes. The stock is down by about -33% this year.

uniQure is primarily focused on gene-based therapy for Hemophilia and is currently in the late-stage of clinical trials and another program focuses on Huntingtons disease. The stock is down by about -49% year-to-date.

What if youre looking for a more balanced portfolio instead? Heres a high-quality portfolio to beat the market, with over 100% return since 2016, versus 50% for the S&P 500. Comprised of companies with strong revenue growth, healthy profits, lots of cash, and low risk, it has outperformed the broader market year after year, consistently.

See allTrefis Price EstimatesandDownloadTrefis Datahere

Whats behind Trefis? See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams |Product, R&D, and Marketing Teams

See the article here:
Gene Therapy Stocks Continue To Underperform. Are They Worth A Look? - Forbes

This entry was posted on October 2, 2020 at 10:57 am and is filed under Gene therapy. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |